Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug eye risk under microscope

NCT ID NCT07602348

Knowledge-focused Sponsor: University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how newer diabetes medications (SGLT2 inhibitors and GLP-1 receptor agonists) affect the eyes of people with type 2 diabetes. Researchers will monitor 40 adults who take metformin and are starting these newer drugs. The goal is to see if these drugs cause any changes in the retina or vision, and how those changes relate to blood vessel health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Mar 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals with type 2 diabetes mellitus (T2DM), diagnosed according to the criteria established by the EASD and the ADA, with and without diabetic retinopathy, who are receiving metformin therapy. Participants will receive, in addition to metformin, either GLP-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals aged ≥18 years. 2. Male and/or female patients with T2DM diagnosed according to the criteria established by the EASD and the ADA. 3. Patients receiving only metformin as antidiabetic treatment. 4. Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists. 5. Patients who are able to provide informed consent for participation in the study. Exclusion Criteria: 1. Patients who are pregnant or breastfeeding. 2. History of multiple severe hypoglycaemic episodes during the past two years. 3. History of ketoacidosis or metabolic acidosis. 4. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis. 5. Patients who have undergone panretinal photocoagulation within the last 6 months. 6. Patients who have received intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy or corticosteroids within the last 6 months. 7. Patients who have undergone cataract surgery or vitrectomy within the last 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy retinal vascular disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy Endothelial dysfunction GLP-1 Microvascular circulation Retinal vascular diseases SGLT 2 inhibitors

Contacts and locations

Locations

  • 2nd Department of Ophthalmology, Attikon University Hospital, National and Kapodistrian University of Athens

    Athens, Attica, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.